AxoGen AXGN 深 滬
等待開盤 10-04 09:30:00 美东时间
17.88
0.000
0.00%
華盛通- 最 高18.64
- 今 開18.02
- 成交量 101.84万股
- 最 低 17.73
- 昨 收 17.88
- 總市值 8.23亿
- 52周最高 21.00
- 市盈率 靜 --
- 換手率 2.21%
- 52周最低 9.215
- 委 比 -64.50%
- 總股本 4601.26万
- 歷史最高 56.85
- 量 比 0.92
- 振 幅 5.09%
- 歷史最低 1.10
- 每 手 1
- 風險率 2.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
HC Wainwright & Co. Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. analyst Yi Chen initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Target of $25.
09-30 18:56
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. announced that its management will participate in four upcoming investor conferences in September 2025. The company, a global leader in peripheral nerve regeneration solutions, will engage in fireside chats and 1x1 investor meetings across key healthcare conferences in NYC and Boston. Axogen is focused on developing innovative surgical solutions to restore peripheral nerve function, offering products like Avance® Nerve Graft and Axog...
08-27 12:00
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index falling more than 200 points o...
08-26 00:02
FDA Extends Review for AxoGen’s Avance Nerve Graft
AxoGen ( ($AXGN) ) has issued an update. On August 22, 2025, Axogen, Inc. annou...
08-25 18:58
Axogen Receives FDA Major Amendment Designation, Delaying Avance Nerve Graft Decision
Axogen, Inc. (NASDAQ:AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance®
08-25 18:46
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
The U.S. Food and Drug Administration (FDA) has extended the PDUFA goal date for Axogen, Inc.'s Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025. This change follows the submission of a Major Amendment to the BLA, which included new manufacturing and facility data. The FDA also anticipates providing feedback on product labeling in November 2025.
08-25 10:40
Axogen shares are trading higher after the company reported better-than-expected Q2 financial results.
Axogen shares are trading higher after the company reported better-than-expecte...
08-05 20:30
Axogen Narrows FY2025 Sales Guidance from $215.439M-$219.185M to $219.000M vs $216.463M Est
Axogen (NASDAQ:AXGN) narrows FY2025 sales outlook from $215.439 million-$219.185 million to $219.000 million vs $216.463 million estimate.
08-05 19:04
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
